促红细胞生成素作为电休克治疗认知副作用附加治疗:随机对照试验研究方案
本随机对照试验方案拟纳入52例当前中度至重度抑郁、转诊接受电休克治疗(ECT)的单相或双相障碍患者,双盲随机接受4次高剂量促红细胞生成素(EPO,40,000 IU/ml)或安慰剂(生理盐水)输注,评估EPO能否减轻ECT认知副作用及其是否持久,并用结构与功能MRI探索神经基础及氧化应激、炎症、神经可塑性标志物变化。
要点
- EPO于首次ECT前24小时内首剂输注,其后在第1、4、7次ECT后即刻每周输注一次。
- 主要结局为基线至末次输注后(8次ECT后3天)认知复合评分变化,涵盖注意、精神运动速度和执行功能。
- 样本量N=52(每组26例),在5%双侧α水平下对主要结局组间差异有≥80%把握度。
核心结论
- 该方案旨在检验短期附加EPO能否减轻ECT认知副作用及其持久性,并探索其神经基础与相关生物标志物变化。
研究设计与样本
- 双盲、随机、安慰剂对照、平行组设计,纳入52例当前中度至重度抑郁并转诊ECT的单相或双相障碍患者,随机接受4次高剂量EPO(40,000 IU/ml)或安慰剂(生理盐水)输注。
- 认知评估在基线、末次EPO/生理盐水输注后(8次ECT后3天)及ECT疗程结束后3个月随访时进行。
- 末次EPO/生理盐水输注后以结构与功能MRI探索EPO潜在认知获益的神经基础。
- 行为、情绪与血液生物标志物数据采用重复测量协方差分析,功能MRI数据以FMRIB Software Library预处理和分析。
主要发现
- 原文未报告研究结果,本文件为研究方案。
关键数值与推荐
- 主要结局为基线至EPO治疗结束后(8次ECT后3天)认知复合评分变化,涵盖注意、精神运动速度和执行功能。
- 以N=52(每组26例)在5%α水平(双侧检验)下对主要结局组间差异具有≥80%把握度。
- 首次EPO/生理盐水输注在首次ECT前24小时内,随后三次分别在第1、4、7次ECT后即刻按周间隔输注。
临床怎么用
- 若EPO被证实可减轻ECT认知副作用,可能影响未来抑郁治疗策略及对ECT相关认知障碍神经生物学病因的理解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Electroconvulsive therapy (ECT) is the most effective treatment for severe depression, but its use is impeded by its cognitive side effects. Novel treatments that can counteract these side effects may therefore improve current treatment strategies for depression. The present randomized trial investigates (1) whether short-term add-on treatment with erythropoietin (EPO) can reduce the cognitive side -effects of ECT and (2) whether such effects are long-lasting. Further, structural and functional magnetic resonance imaging (MRI) will be used to explore the neural underpinnings of such beneficial effects of EPO. Finally, the trial examines whether potential protective effects of EPO on cognition are accompanied by changes in markers of oxidative stress, inflammation, and neuroplasticity. METHODS/DESIGN: The trial has a double-blind, randomized, placebo-controlled, parallel group design. Patients with unipolar or bipolar disorder with current moderate to severe depression referred to ECT (N = 52) are randomized to receive four high-dose infusions of EPO (40,000 IU/ml) or placebo (saline). The first EPO/saline infusion is administered within 24 h before the first ECT. The following three infusions are administered at weekly intervals immediately after ECT sessions 1, 4, and 7. Cognition assessments are conducted at baseline, after the final EPO/saline infusion (3 days after eight ECT sessions), and at a 3 months follow-up after ECT treatment completion. The neuronal substrates for potential cognitive benefits of EPO are investigated with structural and functional MRI after the final EPO/saline infusion. The primary outcome is change from baseline to after EPO treatment (3 days after eight ECT sessions) in a cognitive composite score spanning attention, psychomotor speed, and executive functions. With a sample size of N = 52 (n = 26 per group), we have ≥ 80% power to detect a clinically relevant between-group difference in the primary outcome measure at an alpha level of 5% (two-sided test). Behavioral, mood, and blood-biomarker data will be analyzed using repeated measures analysis of covariance. Functional MRI data will be preprocessed and analyzed using the FMRIB Software Library. DISCUSSION: If EPO is found to reduce the cognitive side effects of ECT, this could have important implications for future treatment strategies for depression and for the scientific understanding of the neurobiological etiology of cognitive dysfunction in patients treated with ECT. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03339596 . Registered on 10 November 2017.
引用
- Schmidt LS, Petersen JZ, Vinberg M, et al. Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. Trials. 2018. PMID: 29673379. doi:10.1186/s13063-018-2627-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。